by Raynovich Rod | Jun 14, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
BIO International 2016 : “Imagine Who You will Meet” was an Appropriate Theme Healthcare Disruption Is Creating Reform BIO 2016 was an excellent meeting as usual because of the opportunity to hear thought leaders, policy makers, scientists and make...
by Rod Raynovich | Apr 27, 2010 | RAG
Missed Opportunity in Health Reform-Wellness and Prevention On Monday April 26 a panel of executives and leaders including Michael Milken, moderated by CNBC anchor Maria Bartiromo convened to discuss Health Reform in a session focused on “Prevention and...
by Rod Raynovich | Mar 22, 2010 | BIOgraph
Healthcare and biotech stocks were up today as expected following passage of the historic reform bill. Although there is a considerable amount of work to be done in enabling the historic legislation, uncertainty has been removed and the market can play it out. Many...
by Rod Raynovich | Mar 9, 2010 | BIOgraph, Macro
There is a simple reason why healthcare reform is so hard to do-there has to be winners and losers. We have had many months of discussion on how to pay for healthcare reform such as cuts in Medicare, concessions from Big Pharma, more competition across state lines,...
by Rod Raynovich | Jan 15, 2009 | Biopharmaceuticals, Clinical Diagnostics and Tools
JPMorgan Healthcare Conference Monday briefing: Rod Raynovich Webcast at: https://events.jpmorgan.com Biotech Valuations at trough levels About 4000 attendees consisting of mutual and hedge fund investors,VC’s, Company executives and their PR legions registered the...
